spacer
home > ebr > summer 2017 > complex characters
PUBLICATIONS
European Biopharmaceutical Review

Complex Characters

Oligonucleotides are biopolymers consisting of modified ribonucleotide or deoxynucleotide monomer units. Since they play such a critical role at the human cellular level, they are being developed by several biopharmaceutical organisations as potential therapies and vaccines and are considered to be their own unique modality, distinct from traditional small molecule drugs and biologics.

The FDA has approved a number of these biopolymers, including fomivirsen, pegaptanib and mipomersen, primarily antisense oligonucleotides (ASOs), with several more on the way. In Europe, the Committee for Medicinal Products for Human Use, a division of the EMA, has recently recommended nusinersen for approval. n 100 oligonucleotide drugs progressing through the development pipeline, designed to target diseases and rare genetic disorders, including Huntington’s disease, asthma and certain types of cancer, as well as vaccines for the Ebola, Zika and influenza viruses.

Brief Background

Messenger RNA (mRNA) is a type of oligonucleotide that is critical to the translation of genetic sequence information of DNA into the specific amino acid array of proteins manufactured in the ribosomes of a cell’s cytoplasm. In eukaryote human cells, mRNA consists of several distinct regions. This naturally occurring sequence is known as the sense sequence.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jon S Kauffman, PhD, is Senior Director of Biopharmaceutical Services and Method Development and Validation at Eurofins Lancaster Laboratories. With more than 25 years of analytical testing experience, he oversees departments responsible for developing and validating methods and performing analysis of clinical and commercial samples for stability and release purposes. Jon earned a doctorate in chemistry from the University of Delaware, US.
spacer
Jon S Kauffman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals enters into manufacturing agreement with the Swedish company Affibody

[Noáin, May 27, 2019] 3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics, has signed a collaboration agreement with the Swedish company Affibody for the process transfer, scale-up and GMP commercial manufacturing of a recombinant protein sole property of Affibody.
More info >>

White Papers

Securing the Global Pharmaceutical Supply Chain against the Threat of Counterfeit Drugs

World Courier

With a fully integrated GxP-compliant transport, storage and distribution system in place and over 140 wholly owned ISO 9001 - certified offices in more than 50 countries, WORLD COURIER, an AmerisourceBergen® company, is the world’s largest and most experienced provider of specialty courier services. It is uniquely positioned to meet the most demanding industry requirements for managing the global distribution of time - and temperaturesensitive pharmaceutical products and IMPs used commercially or in clinical trials.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement